Tag: NYSE:MDT

Advisor Group Holdings Inc. increased its position in shares of Medtronic plc (NYSE:MDT – Get Rating) by 11.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 609,610 shares of the medical technology company’s stock after buying an additional 62,922 shares during the period. Advisor Group Holdings Inc.’s holdings in Medtronic were worth $47,407,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in MDT. Vanguard Group Inc. lifted its stake in shares of Medtronic by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 123,861,994 shares of the medical technology company’s stock worth $10,001,857,000 after purchasing an additional 1,056,995 shares during the last quarter. BlackRock Inc. lifted its position in shares of Medtronic by 5.1% during the third quarter. BlackRock Inc. now owns 115,998,561 shares of the medical technology company’s stock valued at $9,366,883,000 after buying an additional 5,620,477 shares during the last quarter. State Street Corp boosted its holdings in shares of Medtronic by 1.6% in the 3rd quarter. State Street Corp now owns 58,989,713 shares of the medical technology company’s stock valued at $4,802,998,000 after buying an additional 928,929 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Medtronic by 33.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,374,686 shares of the medical technology company’s stock worth $1,564,508,000 after buying an additional 4,816,172 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Medtronic by 4.6% during the 3rd quarter. Royal Bank of Canada now owns 13,702,223 shares of the medical technology company’s stock worth $1,106,453,000 after acquiring an additional 608,587 shares in the last quarter. 80.37% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MDT has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Medtronic from $80.00 to $87.00 in a report on Wednesday, February 22nd. Royal Bank of Canada reissued a “sector perform” rating and issued a $89.00 price target on shares of Medtronic in a report on Friday, April 21st. Wells Fargo & Company upgraded shares of Medtronic from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $77.00 to $100.00 in a report on Monday, April 24th. Truist Financial lifted their target price on shares of Medtronic from $88.00 to $93.00 in a research note on Monday, April 24th. Finally, Mizuho cut their price target on shares of Medtronic from $100.00 to $95.00 and set a “buy” rating on the stock in a research note on Tuesday, January 24th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $90.11.

Medtronic Stock Performance

MDT opened at $89.50 on Tuesday. The firm has a fifty day moving average price of $84.32 and a 200 day moving average price of $82.04. Medtronic plc has a 1 year low of $75.76 and a 1 year high of $106.06. The stock has a market cap of $119.07 billion, a P/E ratio of 29.44, a P/E/G ratio of 2.15 and a beta of 0.71. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.76 and a quick ratio of 1.39.

Medtronic (NYSE:MDT – Get Rating) last posted its earnings results on Tuesday, February 21st. The medical technology company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.03. The business had revenue of $7.70 billion for the quarter, compared to analyst estimates of $7.53 billion. Medtronic had a net margin of 13.20% and a return on equity of 13.37%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the prior year, the company posted $1.37 EPS. Equities research analysts anticipate that Medtronic plc will post 5.28 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 14th. Stockholders of record on Friday, March 24th were given a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date of this dividend was Thursday, March 23rd. Medtronic’s dividend payout ratio (DPR) is presently 89.47%.

Medtronic Company Profile

(Get Rating)

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

Read More

Receive News & Ratings for Medtronic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medtronic and related companies with MarketBeat.com’s FREE daily email newsletter.

Glass Jacobson Investment Advisors llc bought a new position in Medtronic plc (NYSE:MDT – Get Rating) in the 4th quarter, Holdings Channel.com reports. The fund bought 1,000 shares of the medical technology company’s stock, valued at approximately $78,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Brinker Capital Investments LLC increased its position in shares of Medtronic by 6.7% in the 4th quarter. Brinker Capital Investments LLC now owns 40,243 shares of the medical technology company’s stock worth $3,128,000 after purchasing an additional 2,535 shares during the last quarter. Westpac Banking Corp increased its position in shares of Medtronic by 0.4% in the 4th quarter. Westpac Banking Corp now owns 114,823 shares of the medical technology company’s stock worth $8,924,000 after purchasing an additional 463 shares during the last quarter. Bogart Wealth LLC increased its position in shares of Medtronic by 20.3% in the 4th quarter. Bogart Wealth LLC now owns 46,998 shares of the medical technology company’s stock worth $3,653,000 after purchasing an additional 7,945 shares during the last quarter. Ropes Wealth Advisors LLC increased its position in shares of Medtronic by 14.3% in the 4th quarter. Ropes Wealth Advisors LLC now owns 3,981 shares of the medical technology company’s stock worth $309,000 after purchasing an additional 497 shares during the last quarter. Finally, Glassman Wealth Services increased its position in shares of Medtronic by 9.5% in the 4th quarter. Glassman Wealth Services now owns 2,705 shares of the medical technology company’s stock worth $210,000 after purchasing an additional 235 shares during the last quarter. Institutional investors own 80.37% of the company’s stock.

Medtronic Trading Down 0.5 %

Shares of NYSE:MDT opened at $90.95 on Friday. The company has a 50 day moving average of $81.86 and a 200-day moving average of $81.47. The firm has a market cap of $121.00 billion, a P/E ratio of 29.92, a P/E/G ratio of 2.16 and a beta of 0.71. Medtronic plc has a twelve month low of $75.76 and a twelve month high of $106.63. The company has a current ratio of 1.76, a quick ratio of 1.39 and a debt-to-equity ratio of 0.43.

Medtronic (NYSE:MDT – Get Rating) last issued its quarterly earnings results on Tuesday, February 21st. The medical technology company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.03. The company had revenue of $7.70 billion during the quarter, compared to analyst estimates of $7.53 billion. Medtronic had a net margin of 13.20% and a return on equity of 13.37%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.37 EPS. As a group, analysts anticipate that Medtronic plc will post 5.28 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 14th. Stockholders of record on Friday, March 24th were paid a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend was Thursday, March 23rd. Medtronic’s dividend payout ratio is currently 89.47%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MDT. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Medtronic from $80.00 to $87.00 in a report on Wednesday, February 22nd. Mizuho decreased their price target on shares of Medtronic from $100.00 to $95.00 and set a “buy” rating for the company in a report on Tuesday, January 24th. UBS Group lowered shares of Medtronic from a “buy” rating to a “sell” rating and decreased their price target for the company from $127.00 to $79.00 in a report on Wednesday, March 29th. StockNews.com began coverage on shares of Medtronic in a report on Thursday, March 16th. They issued a “buy” rating for the company. Finally, Wells Fargo & Company raised shares of Medtronic from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $77.00 to $100.00 in a report on Monday, April 24th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $91.79.

About Medtronic

(Get Rating)

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

Featured Stories

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Get Rating).

Receive News & Ratings for Medtronic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medtronic and related companies with MarketBeat.com’s FREE daily email newsletter.

Cetera Advisors LLC cut its position in Medtronic plc (NYSE:MDT – Get Rating) by 30.5% in the second quarter, Holdings Channel reports. The firm owned 39,489 shares of the medical technology company’s stock after selling 17,306 shares during the period. Cetera Advisors LLC’s holdings in Medtronic were worth $3,544,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in MDT. Vanguard Group Inc. boosted its position in shares of Medtronic by 6.5% in the 1st quarter. Vanguard Group Inc. now owns 120,557,488 shares of the medical technology company’s stock valued at $13,375,853,000 after purchasing an additional 7,403,778 shares during the period. Invesco Ltd. boosted its position in shares of Medtronic by 29.6% in the 1st quarter. Invesco Ltd. now owns 12,205,798 shares of the medical technology company’s stock valued at $1,354,234,000 after purchasing an additional 2,789,882 shares during the period. Bridgewater Associates LP acquired a new stake in shares of Medtronic in the 1st quarter valued at about $208,596,000. Sanders Capital LLC boosted its position in shares of Medtronic by 14.3% in the 1st quarter. Sanders Capital LLC now owns 13,517,677 shares of the medical technology company’s stock valued at $1,660,016,000 after purchasing an additional 1,687,707 shares during the period. Finally, Capital Research Global Investors lifted its position in Medtronic by 6.8% during the 1st quarter. Capital Research Global Investors now owns 22,023,597 shares of the medical technology company’s stock worth $2,443,518,000 after acquiring an additional 1,405,249 shares during the period. 79.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Morgan Stanley decreased their price objective on Medtronic from $101.00 to $97.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 11th. Citigroup decreased their price objective on Medtronic from $110.00 to $108.00 in a research report on Wednesday, October 5th. Wells Fargo & Company decreased their price objective on Medtronic from $104.00 to $96.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 24th. Royal Bank of Canada decreased their price objective on Medtronic from $122.00 to $110.00 in a research report on Wednesday, September 7th. Finally, Piper Sandler reduced their price target on Medtronic from $100.00 to $90.00 in a report on Tuesday, August 23rd. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $106.75.

Medtronic Stock Performance

Medtronic stock opened at $82.29 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.23 and a current ratio of 1.58. The stock has a fifty day moving average of $84.04 and a two-hundred day moving average of $90.04. The company has a market capitalization of $109.38 billion, a price-to-earnings ratio of 21.26, a PEG ratio of 2.17 and a beta of 0.77. Medtronic plc has a fifty-two week low of $79.19 and a fifty-two week high of $118.80.

Medtronic (NYSE:MDT – Get Rating) last announced its quarterly earnings data on Tuesday, August 23rd. The medical technology company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.01. The business had revenue of $7.37 billion during the quarter, compared to the consensus estimate of $7.20 billion. Medtronic had a return on equity of 13.64% and a net margin of 16.75%. During the same quarter in the previous year, the business earned $1.41 earnings per share. On average, analysts anticipate that Medtronic plc will post 5.52 EPS for the current fiscal year.

Insider Activity

In other news, EVP Hoedt Rob Ten sold 2,404 shares of Medtronic stock in a transaction on Friday, October 14th. The stock was sold at an average price of $81.54, for a total value of $196,022.16. Following the completion of the sale, the executive vice president now owns 43,483 shares of the company’s stock, valued at $3,545,603.82. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.29% of the company’s stock.

About Medtronic

(Get Rating)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Featured Stories

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Get Rating).

Receive News & Ratings for Medtronic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medtronic and related companies with MarketBeat.com’s FREE daily email newsletter.